Sort   by:  
 Page size 
MetabolomicsDe Novo Pyrimidine Synthesis Is a Collateral Metabolic Vulnerability in NF2-deficient Mesothelioma

Pleural mesothelioma (PM) is one of the deadliest cancers, with limited therapeutic options due to its therapeutically intractable genome, which is characterized by the functional inactivation of tumor suppressor genes (TSGs) and high tumor heterogeneity, including diverse metabolic adaptations. ...

2025-07-07 | MTBLS12461 | MetaboLights
TranscriptomicsMerlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus
Current models imply that the FERM domain protein Merlin, encoded by the tumor suppressor NF2, inhibits mitogenic signaling at or near the plasma membrane. Here, we show that the closed, growth inhibitory form of Merlin accumulates in the nucleus, binds to the E3 ubiquitin ligase CRL4DCAF1, and supp...
ORGANISM(S): Mus musculus 
2010-03-09 | E-GEOD-19305 | biostudies-arrayexpress
TranscriptomicsGenomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
We report genomic analysis of 300 meningiomas, the most common primary brain tumors, leading to the discovery of mutations in TRAF7, a proapoptotic E3 ubiquitin ligase, in nearly one-fourth of all meningiomas. Mutations in TRAF7 commonly occurred with a recurrent mutation (K409Q) in KLF4, a transcri...
ORGANISM(S): Homo sapiens 
2014-05-29 | E-GEOD-58037 | biostudies-arrayexpress
TranscriptomicsTherapeutic potential of a novel HSP90 Inhibitor, NXD30001, for Neurofibromatosis type 2
Purpose: The growth and survival of NF2-deficient cells are enhanced by the activation of multiple signaling pathways including ErbB2/IGF-1R/Met, PI3K/Akt, and Ras/Raf/Mek/Erk1/2. The ubiquitously expressed chaperone protein HSP90 is known to be essential for the stabilization of these signaling mol...
ORGANISM(S): Mus musculus 
2013-06-06 | E-GEOD-40187 | biostudies-arrayexpress
ProteomicsIntegrated proteomic, DNA methylation, and targeted Next Generation Sequencing reveals relevant heterogeneity in lower-grade meningioma and a new target in NF2 mutated meningiomas
Meningiomas, the most common primary brain tumours, are classified by the World Health Organization (WHO) into grades 1, 2, and 3. Some grade 1 tumours exhibit increased clinical aggressiveness with the biallelic mutation of Neurofibromatosis 2 (NF2) being the most frequent mutation reported. In our...
ORGANISM(S): Homo sapiens (Human) 
2025-07-02 | PXD058653 | Pride
Genomics Nf2 Proteomics Meningioma 
GenomicsAeromonas hydrophila strain:NF2
Aeromonas hydrophila NF2 Genome sequencing
PRJNA237917 | ENA
ProteomicsDe Novo Pyrimidine Synthesis Is a Collateral Metabolic Vulnerability in NF2-deficient Mesothelioma
Pleural mesothelioma (PM) is one of the deadliest cancers, with limited therapeutic options due to its therapeutically intractable genome, which is characterized by the functional inactivation of tumor suppressor genes (TSGs) and high tumor heterogeneity, including diverse metabolic adaptations. How...
ORGANISM(S): Homo sapiens (Human) 
2025-07-08 | PXD063342 | Pride
Metabolic diversity De novo pyrimidine synthesis Neurofibromin 2 (nf2) Pleural mesothelioma (pm) Synthetic lethality 
TranscriptomicsGene expression signature regulated by cell density and Merlin/NF2 knockdown in HMLE cells
Merlin has been implicated in contact-dependent inhibition of proliferation To define genes regulated by Merlin and study their relationship to cell density-dependent gene expression, microarray experiments were performed after Merlin depletion in HMLE cells at both high and low cell densities. HMLE...
ORGANISM(S): Homo sapiens 
2015-04-01 | E-GEOD-53493 | biostudies-arrayexpress
GenomicsCombining brigatinib with mTOR inhibition to effectively treat NF2-SWN-associated and sporadic NF2-deficient meningiomas
Combining brigatinib with mTOR inhibition to effectively treat NF2-SWN-associated and sporadic NF2-deficient meningiomas
PRJNA1315147 | ENA
GenomicsGene expression changes in HEI-193 (NF2-deficient Schwannoma) cells by NF2-restoring or TEW7197 treatment.
Gene expression changes in HEI-193 (NF2-deficient Schwannoma) cells by NF2-restoring or TEW7197 treatment.
PRJNA474687 | ENA
Sort   by:  
 Page size